CLAIMS
1. A compound represented by the formula (la) or a
pharmacologically acceptable salt thereof:
wherein
two R moieties each independently are a Ci_3 alkyl group or are groups bonded to each other to form a C2-5 alkylene group;
A is an optionally substituted Ce-io aryl group or an optionall) substituted heteroaryl group, and Z is a hydrogen atom or an optionally substituted CM alkyl group, or a group represented by Z-N-A forms ar optionally substituted bicyclic fused heterocyclic group through the bonding between A and Z; and
R , R and R each independently are an optionally substitutec linear or branched CM alkyl group.
2. A compound represented by the formula (I) or i
pharmacologically acceptable salt thereof:

two R moieties each independently are a Ci_3 alkyl group or are groups bonded to each other to form a C2-5 alkylene group;
A is an optionally substituted C6-10 aryl group or an optionally substituted heteroaryl group; and
R , R and R each independently are an optionally substituted linear or branched CM alkyl group.
3. A compound represented by the formula (Ha) or a
pharmacologically acceptable salt thereof:
wherein
A is an optionally substituted C6_i0 aryl group or an optionally substituted heteroaryl group, and Z is a hydrogen atom or an optionally substituted Ci_6 alkyl group, or a group represented by Z-N-A forms an optionally substituted bicyclic fused heterocyclic group through the bonding between A and Z; and
R , R and R each independently are an optionally substituted linear or branched CM alkyl group.
4. A compound represented by the formula (II) or a
pharmacologically acceptable salt thereof: [Chemical Formula 4]

wherein
A is an optionally substituted C^io aryl group or an optionally substituted heteroaryl group; and
R , R and R each independently are an optionally substituted linear or branched Ci_4 alkyl group.
5. A compound represented by the formula (Ilia) or a
pharmacologically acceptable salt thereof:
wherein
A is an optionally substituted Ce-io aryl group or an optionally substituted heteroaryl group, and Z is a hydrogen atom or an optionally substituted Ci_6 alkyl group, or a group represented by Z-N-A forms an optionally substituted bicyclic fused heterocyclic group through the bonding between A and Z; and
R , R and R each independently are an optionally substituted linear or branched C1.4 alkyl group.
6. A compound represented by the formula (III) or a
pharmacologically acceptable salt thereof:

wherein
A is an optionally substituted C6.10 aryl group or an optionally substituted heteroaryl group; and
R , R and R each independently are an optionally substituted linear or branched C1.4 alkyl group.
7. A compound represented by the formula (IVa) or a
pharmacologically acceptable salt thereof:
wherein
A is an optionally substituted Ce-io aryl group or an optionally substituted heteroaryl group, and Z is a hydrogen atom or an optionally substituted Ci_6 alkyl group, or a group represented by Z-N-A forms an optionally substituted bicyclic fused heterocyclic group through the bonding between A and Z; and
R , R and R each independently are an optionally substituted
linear or branched C1.4 alkyl group.
8. A compound represented by the formula (IV) or a

wherein
A is an optionally substituted Ce-io aryl group or an optionally substituted heteroaryl group; and
R , R and R each independently are an optionally substituted linear or branched Ci_4 alkyl group.
9. A compound selected from the compound group consisting of
6,6-Dimethyl-N-phenyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, 6,6-Dfmethyl-N-(p-tolyl)-3-[l-(trimethylsilyl)cyclobutanecarboxamido] -4,6~dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, N-(4-methoxyphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecar boxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, N~(4-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarbo xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(IH)-carboxamide, 6,6-Dimethyl-N-(pyridin-3-yl)-3-[l-(trimethylsilyl)cyclobutanecarboxa mido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, N-(2-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarbo xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, 6,6-Dimethyl-N~(o-tolyl)-3-[l-(trimethylsilyl)cyclobutanecarboxamido] -4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,

6,6-Dimethyl"N-(m-tolyl)-3-[l-(trimethylsilyl)cyclobutanecarboxamido
]-4,6-dihydropyrrolo[3,4-c]pyrazole~5(lH)-carboxamide,
N-([l,r-biphenyl]-3-yl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanec
arboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(3-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarbo
xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(3-chlorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarbo
xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2-methoxyphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecar
boxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2-chlorophenyl)-6,6-dimethyl-3 - [ 1 -(trimethylsilyl)cyclobutanecarbo
xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-([l,l'-biphenyl]-2-yl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanec
arboxamido]-4,6-dihydropyrrolo[3,4~c]pyrazole-5(lH)-carboxamide,
6,6-Dimethyl-N-(pyridin-2-yl)-3"[l-(trimethylsilyl)cyclobutanecarboxa
mido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2-ethylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarbox
amido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide;
N-(2,6-dimethylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanec
arboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2,3-difluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutaneca
rboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2,3-dimethylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanec
arboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2-fluoro-6-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid

e,
N- [2-(difluoromethoxy)phenyl]-6,6-dimethyl-3 - [ 1 -(trimethylsilyl)cyclo
butanecarboxamido]-4?6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxa
mide,
N-(2-ethoxyphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarbo
xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
6,6-Dimethyl-N-[2-(trifluoromethoxy)phenyl]-3-[l-(trimethylsilyl)cyclo
butanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxa
mide,
N-(2-fluoro-4-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
N-(2,6-difluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutaneca
rboxamido]-4,6-dihydropyrrolo[354-c]pyrazole-5(lH)-carboxamide,
N-[2-(tert-butyl)phenyl]-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanec
arboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
6,6-Dimethyl-N-[2-(trifluoromethyl)phenyl]-3-[l-(trimethylsilyl)cyclob
utanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxam
ide,
N-(3 -fluoro-2-methylphenyl)-6,6-dimethyl-3- [ 1 -(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
N-(2-cyanophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarbo xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, N-(4-fluoro-2-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid

e,
N-(2-chloro-6-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobu
tanecarboxamido]-4,6~dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxami
de,
N-(2-fluoro-3-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
N-(2-fluoro-5-methylphenyl)-6,6~dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
N-(5-fluoro-2-methylphenyl)~6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
N-(2,4-difluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutaneca
rboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2,5-difluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutaneca
rboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole"5(lH)-carboxamide,
N-(2,5-dimethylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanec
arboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2-chloro-6-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4"C]pyrazole-5(lH)-carboxamid
e,
N-(2,4-dimethylphenyl)-6,6-dimethyl-3~[l-(trimethylsilyl)cyclobutanec arboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, 3-[l-(Ethyldimethylsilyl)cyclobutanecarboxamido]-N-(2-fluorophenyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,

6,6-Dimethyl-N-(3-methylisothiazol-4-yl)-3-[l-(trimethylsilyl)cyclobut anecarboxamido]-4,6-dihydropyrrolo[3;4-c]pyrazole-5(lH)-carboxamid
e,
6,6-Dimethyl-N-(thiophen-2-yl)-3-[l-(trimethylsilyl)cyclobutanecarbox
amido]-2,6-dihydropyrrolo[3,4~c]pyrazole-5(lH)-carboxamide,
6,6-Dimethyl-N-(thiophen-3-yl)-3-[l-(trimethylsilyl)cyclobutanecarbox
amido]-2,6-dihydropyrrolo[3;4-c]pyrazole-5(lH)-carboxamide,
N-(2,6-difluoro-4-methoxyphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cy
clobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbo
xamide,
N-(2-fluoro-6-methoxyphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclob
utanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxam
ide,
N-[2-fluoro-6-(trifLuoromethyl)phenyl]-6,6-dimethyl-3-[l-(trimethylsily
l)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-c
arboxamide,
N-(5-chloro-2~methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobu
tanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxami
de,
N-(235-dichlorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutaneca
rboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2»cyclopropylphenyl)~6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutane
carboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2,6-dichlorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutaneca
rboxamido]~4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
6,6-Dimethyl-N-(2,4,6-trifluorophenyl)-3-[l-(trimethylsilyl)cyclobutane

carboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2-ethyl-6-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobuta
necarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide
i N-(2-bromophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarbo
xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2-chloro-5-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
N-(5-chloro-2-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
6,6-Dimethyl-N-(2,3,6-trifluorophenyl)-3-[l-(trimethylsilyl)cyclobutane
carboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2-chloro-6-methoxyphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclob
utanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxam
ide,
N-[2-(l,l-difluoroethyl)phenyl]-6,6-dimethyl-3-[l-(trimethylsilyl)cyclo
butanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxa
mide,
N-(6-cMoro-2"fluoro™3-methylphenyl)-6,6-dimethyl-3-[l»(trimethylsilyl
)cyclobutanecarboxamido]-4;6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-ca
rboxamide,
N-(2-fluoro-6-(methoxy-d3)phenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)c
yclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carb
oxamide,

N-[2-chloro-6-(trifluoromethyl)phenyl]-6,6-dimethyl-3-[l-(trimethylsily
l)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-c
arboxamide,
N-(2-fluorO"6-methoxy-3-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsi
lyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3:(4-c]pyrazole-5(lH)-
carboxamide,
N-(2?6-difluoro-3-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cycl
obutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbox
amide,
N-[2-(difluoromethoxy)-6-fluorophenyl]-6,6"dimethyl-3-[l-(trimethylsil
yl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-
carboxamide,
N-(2-bromo-6-chlorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-456-dihydropyrrolo[3,4-c]pyrazole-5(lH)~carboxamid
e,
N-(2-chloro-6-fluoro-3-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl
)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)~ca
rboxamide,
N-(2-ethyl-6-fluorophenyl)-6,6-dimethyl-3 - [ 1 -(trimethylsilyl)cyclobuta
necarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide
N-(2-bromo-6-fluorophenyl)-6,6-dimethyl-3~[l-(trimethylsilyl)cyclobut
anecarboxamido]~4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
N-(2-bromo-6-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobu
tanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazoie-5(lH)-carboxami

de,
N-(2-chloro-5-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobu
tanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxami
de,
N-(6-fluoro-2,3 -dihydrobenzomran-7-yl)-6,6~dimethyl-3 - [ 1 -(trimethylsi
lyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-
carboxamide,
N-(2~cyano-6-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobuta
necarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide
N-(2»chloro-6-cyclopropylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyc
lobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbox
amide,
N-(2-fluoro-3,6-dimethylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cycl
obutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbox
amide,
N-(6-fluorobenzofuran-7-yl)»6,6-dimethyl-3-[l-(trimethylsilyl)cyclobut
anecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
N-(2"Chloro-3-fluoro-6-methylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl
)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-ca
rboxamide,
N-[2-(difluoromethoxy)-6-fluorophenyl]-6,6-dimethyl-3-[l-(trimethylsil
yl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)
-carboxamide,
N-(2,6-dichlorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclopropanec

arboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2,6-dichlorophenyl)-6,6-dimethyl-3-[2-methyl-2-(trimethylsilyl)prop
aneamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)~carboxamide,
N-[2-(difluoromethoxy)-6-fluorophenyl]-6,6~dimethyl-3-[2-methyl-2-(tr
imethylsilyl)propaneamido]-4,6-dihydropyrrolo[334-c]pyrazole-5(lH)-c
arboxamide,
N-(2,6-dichloro-4-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclo
butanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxa
mide,
N-(2-ethyl-6-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cycloprop
anecarboxamido]-4,6~diliydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamid
e,
N-(2-bromo-6-methylphenyl)-6,6-dimethyl-3--[l-(trimethylsilyl)cyclopr
opanecarboxamido]-456-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxa
mide,
N-(2-chloro-5-methoxyphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclob
utanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxam
ide,
N-(2-ethyl-6-fluorophenyl)-6,6-dimethyl-3-[2-methyl-2-(trimethylsilyl)
propaneamido]-4,6-dihydropyrroio[3,4-c]pyrazole-5(lH)-carboxamide,
N-(2-bromo-6-methylphenyl)-6,6-dimethyl-3-[2-methyl-2~(trimethylsily
l)propaneamido]-4?6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide
•>
N-(6-fluorobenzomran-7-yl)-6,6-dimethyl-3-[2~methyl-2-(trimethylsiiyl )propaneamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, N-(6-fluorobenzofliran-7-yl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclopro

panecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxami
de,
N,6,6-trimethyl-N-phenyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido
]-4,6-dmydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide,
N-(6-fLuoro-3-methylbenzofuran-7-yl)-6,6-dimethyl-3-[l-(trimethylsilyl
)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole~5(lH)-ca
rboxamide,
N-(2-chloro-6-fluorobenzofuran-7-yl)-6,6-dimethyl-3-[l-(trimethylsilyI)
cyclobutanecarboxamido]-4,6-dihydropyrrolo[3;4-c]pyrazole-5(lH)-car
> boxamide,
N-[5-(indoline-1 -carbonyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3,4-dihydro-2H-benzo[b] [ 1,4]oxazine-4-carbonyl)-6,6-dimethyl-1 ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobuta
i necarboxamide,
N-(6-fluoro-2-methylbenzofuran-7-yl)-6,6-dimethyl-3-[l-(trimethylsilyl )cyclobutanecarboxamido]-4,6-dihydropyrrolo[3;4-c]pyrazole-5(lH)-ca rboxamide, and N-[5-(lH-indole-l-carbonyl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,
) 4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide
or a pharmacologically acceptable salt thereof. 10.
N-(2-fluorophenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutan ecarboxamido]~4,6-dihydropyrrolo[3,4»c]pyrazole-5(lH)-carboxamide
> or a pharmacologically acceptable salt thereof.
11.

6,6-Dimethyl-N-(o»tolyl)-3-[l-(trimethylsilyl)cyclobutanecarbo xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide or a pharmacologically acceptable salt thereof. 12.
N-(2-chloro-6-methylphenyl)-656-dimethyl-3 - [ 1 -(trimethylsilyl) cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-car boxamide or a pharmacologically acceptable salt thereof. 13.
N-(5 -fluoro-2-methylphenyl)~6,6-dimethyl-3 - [ 1 -(trimethylsilyl)c yclobutanecarboxamido]-4,6-dihydropyrrolo[3?4-c]pyrazole~5(lH)-carb oxamide or a pharmacologically acceptable salt thereof. 14.
N-(2,5-dimethylphenyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclo butanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxa mide or a pharmacologically acceptable salt thereof. 15.
N-(2-chloro-6-fluorophenyl)-6,6-dimethyl-3 - [ 1 -(trimethylsilyl)c yclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carb oxamide or a pharmacologically acceptable salt thereof. 16.
N-(2-bromo-6-methylphenyl)-6,6-dimethyl-3- [ 1 -(trimethylsilyl) cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-car boxamide or a pharmacologically acceptable salt thereof. 17.
N-(2-fluoro-3,6-dimethylphenyl)-6,6-dimethyl-3-[l-(trimethylsil yl)cyclobutanecarboxamido]-4?6-dihydropyrrolo[3,4»c]pyrazole-5(lH)-

carboxamide or a pharmacologically acceptable salt thereof. 18.
N-(6-fluorobenzofuran-7-yl)-6;6-dimethyl-3-[l-(trimethylsilyl)c yclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carb oxamide or a pharmacologically acceptable salt thereof. 19.
N-(2-chloro-6-fluorobenzofuran-7-yl)-6,6-dimethyl-3-[l-(trimet hylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5( lH)-carboxamide or a pharmacologically acceptable salt thereof. 20.
N"(6-fluoro-2-methylbenzofuran-7-yl)-6,6-dimethyl-3-[l-(trimet hylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole»5( lH)-carboxamide or a pharmacologically acceptable salt thereof.
21. A pharmaceutical composition comprising a compound or a pharmacologically acceptable salt thereof according to any one of claims 1 to 20.
22. The pharmaceutical composition according to claim 21, wherein the pharmaceutical composition is a CDK7 inhibitor.
23. The pharmaceutical composition according to claim 21 or 22, wherein the pharmaceutical composition is for the treatment or prevention of a cancer, an inflammatory disease, an allergic disease or a chronic respiratory disease.
24. The pharmaceutical composition according to claim 23, wherein the cancer is a blood cancer or a solid cancer.
25. The pharmaceutical composition according to claim 24, wherein the blood cancer is multiple myeloma, chronic myelogenous leukemia,

blood tumor, hematological malignancy, childhood leukemia, childhood lymphoma, Hodgkin's disease, lymphocytic lymphoma, cutaneous lymphoma, acute leukemia, chronic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, plasma cell neoplasm, lymphoid neoplasm or AIDS-related cancer.
26. The pharmaceutical composition according to claim 24, wherein the solid cancer is bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, head and neck cancer, esophageal cancer, gallbladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, uterine cervical cancer, thyroid cancer, prostate cancer, skin cancer including squamous cell carcinoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma, glioma and neurilemmoma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, follicular thyroid cancer or Kaposi's sarcoma.
27. The pharmaceutical composition according to claim 23, wherein the inflammatory disease is an autoimmune disease.
28. The pharmaceutical composition according to claim 27, wherein the autoimmune disease is rheumatoid arthritis.
29. The pharmaceutical composition according to claim 27, wherein the autoimmune disease is psoriasis.
30. The pharmaceutical composition according to claim 27, wherein the autoimmune disease is multiple sclerosis.
31. The pharmaceutical composition according to claim 27, wherein the autoimmune disease is inflammatory bowel disease.
32. The pharmaceutical composition according to claim 23, wherein

the chronic respiratory disease is chronic obstructive pulmonary disease.
33. The pharmaceutical composition according to claim 23, wherein the allergic disease is atopic dermatitis.
34. The pharmaceutical composition according to any one of claims 21 to 33, wherein the pharmaceutical composition is administered in combination with one or more additional drug(s) selected from the group consisting of anticancer agents, antirheumatic agents, drugs for the treatment of psoriasis, drugs for the treatment of multiple sclerosis, drugs for the treatment of inflammatory bowel disease, drugs for the treatment of chronic obstructive pulmonary disease and drugs for the treatment of atopic dermatitis.
35. The pharmaceutical composition according to any one of claims 21 to 33, wherein the pharmaceutical composition is administered at the same time with or at a different time from a composition comprising, as an active ingredient, one or more additional drug(s) selected from the group consisting of anticancer agents, antirheumatic agents, drugs for the treatment of psoriasis, drugs for the treatment of multiple sclerosis, drugs for the treatment of inflammatory bowel disease, drugs for the treatment of chronic obstructive pulmonary disease and drugs for the treatment of atopic dermatitis.
36. The pharmaceutical composition according to any one of claims 21 to 33, further comprising, as an active ingredient, one or more additional drug(s) selected from the group consisting of anticancer agents, antirheumatic agents, drugs for the treatment of psoriasis, drugs for the treatment of multiple sclerosis, drugs for the treatment of inflammatory bowel disease, drugs for the treatment of chronic

obstructive pulmonary disease and drugs for the treatment of atopic dermatitis.
37. The pharmaceutical composition according to any one of claims 34 to 36, wherein the additional drug is selected from the group consisting of tyrosine kinase inhibitors, immune checkpoint inhibitors, DNA alkylating agents, DNA synthesis inhibitors, platinum-containing drugs, antimetabolites, topoisomerase I inhibitors, topoisomerase II inhibitors, tubulin activator, hormone antagonists, aromatase inhibitors, differentiation inducers, proteosome inhibitors, phospholipid kinase inhibitors, adenosine deaminase inhibitors, antiangiogenic agents, histone deacetylase (HDAC) inhibitors, BET bromodomain inhibitors, histone demethylase inhibitors, histone methyltransferase inhibitors, matrix metalloprotease inhibitors, farnesyltransferase inhibitors, bisphosphonate preparations, Hsp90 inhibitors, kinesin Eg5 inhibitors, serine threonine kinase inhibitors, anticytokine agents, immunosuppressants, immunomodulators, active form of vitamin D3 external agent, S1P1 receptor antagonists, interferon preparations, anticholinergic drugs, leukotriene antagonists, PDE4 inhibitors, PGD2 receptor antagonists, neutrophil elastase inhibitors, antihistamine agents, classical non-steroidal anti-inflammatory drugs, cyclooxygenase inhibitors, nitric oxide-releasing non-steroidal anti-inflammatory drugs, gold preparations, penicillamine, aminosalicylic acid preparations, antimalarial drugs, pyrimidine synthesis inhibitors, TNF inhibitors, interleukin inhibitors, interleukin receptor antagonists, interleukin drugs, B-cell activation inhibitors, costimulatory molecule-related protein preparations, MAPK inhibitors, gene regulation drugs, cytokine

production inhibitors, TNF-a-converting enzyme inhibitors,
interleukin-lp-converting enzyme inhibitors, chemokine antagonists,
therapeutic vaccine, gene therapy, antisense compounds, proteasome
inhibitors, JAK inhibitors, T cell inhibitors, inosine monophosphate
dehydrogenase (IMPDH) inhibitors, adhesion molecule inhibitors,
thalidomide, cathepsin inhibitors, glucose~6-phosphate dehydrogenase
inhibitors, dihydroorotate dehydrogenase (DHODH) inhibitors,
phospholipase A2 inhibitors, iNOS inhibitors, microtubule stimulants,
anti-microtubule agents, MHC class II antagonists, CD4 antagonists,
CD23 antagonists, leukotriene B4 receptor antagonists, 5-lipoxygenase
inhibitors, cathepsin B inhibitors, osteogenesis stimulators, dipeptidyl
peptidase inhibitors, collagen agonists, capsaicin creams, sulfa drugs,
hyaluronic acid derivatives, glucosamine sulfate, amiprilose, CD20
inhibitors, CD52 inhibitors, anti-asthmatic drugs, drugs for the
treatment of atopic dermatitis, drugs for the treatment of allergic
rhinitis, opioid receptor agonists, immunoglobulins, glatiramer acetate,
T cell receptor vaccines, adhesion molecule inhibitors, muscle relaxants,
local anesthetics, ketamine, short-acting or long-acting muscarine
receptor antagonists, short-acting and long-acting (3 receptor agonists,
inhaled steroids, oral steroids, combination drugs of P receptor agonists
and inhaled steroids, vitamin derivatives and adrenocortical steroids.
38. The pharmaceutical composition according to any one of claims
34 to 36, wherein the additional drug is selected from the group
consisting of cisplatin, doxorubicin, Taxotere, Taxol, etoposide,
irinotecan, topotecan, paclitaxel, docetaxel, epothilone, tamoxifen,
5-fluorouracil, fmgolimod, methotrexate, temozolomide,

cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662,
gefitinib, erlotinib, panitumumab, afatinib, dasatinib, bosutinib,
vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, lapatinib,
nintedanib, nilotinib, crizotinib, ceritinib, alectinib, ibrutinib, imatinib,
sorafenib, vemurafenib, dabrafenib, trametinib, palbociclib, interferon
alpha-2b, cytarabine, adriamycin, Cytoxan, gemcitabine, uracil mustard,
chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman,
triethylenemelamine, triethylenethiophosphoramine, ofatumumab,
busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine,
6~mercaptopurine, 6-thioguanine, regorafenib, ramucirumab,
fludarabine phosphate, oxaliplatin, folinate, pentostatin, vinblastine,
vincristine, vindesine, bleomycin, dactinomycin, daunorubicin,
doxorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin,
mitomycin-C, L-asparaginase, teniposide, 17oc-ethinylestradiol,
diethylstilbestrol, testosterone, prednisone, fluoxymesterone,
drostanolone propionate, testolactone, megestrol acetate,
methylprednisolone, methyltestosterone, prednisolone, chlorotrianisene,
hydroxyprogesterone, aminoglutethimide, estramustine,
medroxyprogesterone acetate, leuprolide acetate, flutamide, toremifene, goserelin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, Navelbine, anastrozole, letrozole, capecitabine, reloxafme, droloxifene, hexamethylmelamine, bevacizumab, omalizumab, mepolizumab, gemtuzumab ozogamicin, mogamulizumab, pertuzumab, ocrelizumab, alemtuzumab, inotuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, diarsenic trioxide, vinorelbine, porfrmer sodium, thiotepa, altretamine, trastuzumab,

letrozole, fulvestrant, exemestane, rituximab, cetuximab, basiliximab, nivolumab, ipilimumab, pembrolizumab, durvalumab, atezolizumab, avelumab, alcofenac, aceclofenac, sulindac, tolmetin, etodolac, fenoprofen, tiaprofenic acid, meclofenamic acid, meloxicam, tenoxicam, lornoxicam, nabumetone, acetaminophen, phenacetin, ethenzamide, sulpyrine, antipyrine, migrenin, aspirin, mefenamic acid, flufenamic acid, phenylbutazone, indomethacin, ibuprofen, ketoprofen, naproxen, oxaprozin, flurbiprofen, fenbufen, pranoprofen, floctafenine, piroxicam, epirizole, tiaramide hydrochloride, zaltoprofen, gabexate mesilate, camostat mesilate, ulinastatin, colchicine, probenecid, sulfinpyrazone, benzbromarone, allopurinol, brentuximab vedotin, gold sodium thiomalate, sodium hyaluronate, atropine, scopolamine, morphine or salts thereof, pethidine, levorphanol, oxymorphone, celecoxib, etoricoxib, valdecoxib, loxoprofen, auranofm, D-penicillamine, sulfasalazine, mesalazine, olsalazine, balsalazide, chloroquine, leflunomide, tacrolimus, infliximab, etanercept, adalimumab, certolizumab pegol, golimumab, PASSTNF-a, soluble TNF-a receptor, TNF-a-binding protein, anti-TNF-a antibodies, denosumab, anakinra, antibodies against soluble interleukin-1 receptor, tocilizumab, anti-interleukin-6 antibodies, interleukin-10, ustekinumab, briakinumab, secukinumab (AIN-457), ixekizumab (LY-2439821), AMG827, Rituxan, belimumab, abatacept, BMS-582949, inhibitors of molecules involved in signal transduction, MAPK inhibitors, salicylic acid ointments, urea ointments, iguratimod, tetomilast, belnacasan, HMPL-004, IL-8 antagonists, CXCR1-CXCR2 dual antagonists, reparixin, CCR9 antagonists, denileukin diflitox, CCX025,

N-{4-chloro-2-[(l-oxidopyridin-4-yl)carbonyl]phenyl}"4-(propan-2-ylo xy)benzenesulfonamide, MCP-1 antagonists, irbesartan, TNF-a vaccines, ISIS-104838, natalizumab, vedolizumab, AJM300, TRK-170, E6007, MX-68, BMS-188667, CKD-461, rimexolone, cyclosporine A, mizoribine, gusperimus, sirolimus, temsirolimus, everolimus, antilymphocyte serum, freeze-dried sulfonated normal immunoglobulin, erythropoietin, colony-stimulating factors, atiprimod dihydrochloride, azathioprine, interferon a, interferon p-lb, interferon (3-la, tofacitinib, baricitinib, carfilzomib, ruxolitinib, dexamethasone, hexestrol, methimazole, betamethasone, triamcinolone acetonide, fluocinonide, fluocinolone acetonide, cortisone acetate, hydrocortisone, fluorometholone, beclomethasone propionate, estriol, mycophenolate mofetil, alicaforsen sodium, selectin inhibitors, ELAM-1 inhibitors, VCAM-1 inhibitors, ICAM-1 inhibitors, V-85546, roflumilast, apremilast, VAS203, reumacon, zanolimumab, DW-1350, zileuton, Tyk2 inhibitors, Synvisc (hylan G-F 20), Orthovisc, atacicept, blisibimod, tizanidine, eperisone, afloqualone, baclofen, diazepam, dantrolene sodium, vitamin D3 derivatives, vitamin D2 derivatives, isoprenaline hydrochloride, salbutamol sulfate, procaterol hydrochloride, terbutaline sulfate, trimetoquinol hydrochloride, tulobuterol hydrochloride, orciprenaline sulfate, fenoterol hydrobromide, ephedrine hydrochloride, ipratropium bromide, oxitropium bromide, flutropium bromide, theophylline, aminophylline, sodium cromoglicate, tranilast, repirinast, amlexanox, ibudilast, ketotifen, terfenadine, mequitazine, azelastine, ozagrel hydrochloride, pranlukast hydrate, seratrodast, ciclesonide, chlorpheniramine maleate,

alimemazine tartrate, clemastine fumarate, homochlorcyclizine hydrochloride, fexofenadine, ketotifen fumarate, cetirizine hydrochloride, oxatomide, ebastine, epinastine hydrochloride, loratadine, tramadol, promethazine, hydroxyzine, homochlorcyclizine, cyproheptadine, mequitazine, emedastine fumarate, pseudoephedrine, bepotastine besilate, levocetirizine, olopatadine hydrochloride, mycophenolate mofetil, daclizumab, galiximab, metformin hydrochloride, visilizumab, aminopterin, pazopanib hydrochloride, fezakinumab, ruxolitinib phosphate, ixekizumab, guselkumab, SLx-2119, PRX-167700, lidocaine, tiotropium bromide, salmeterol xinafoate, formoterol fumarate, fluticasone propionate, beclometasone propionate, budesonide, and combination drugs of salmeterol xinafoate and fluticasone propionate.
39. The pharmaceutical composition according to any one of claims 34 to 36, wherein the additional drug is 5-fluorouracil.
40. The pharmaceutical composition according to any one of claims 34 to 36, wherein the additional drug is oxaliplatin.
41. The pharmaceutical composition according to any one of claims 34 to 36, wherein the additional drug is irinotecan.